SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Select pharma stocks gain amid neutral outlook for sector

Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 533573 | NSE: APLLTD

20 Mar 2024 Evaluate

Select pharma stocks were trading higher on the BSE, as maintaining a neutral outlook for the pharmaceuticals sector for FY25, credit rating agency, India Ratings and Research (Ind-Ra) in its latest report is expecting pharmaceuticals companies to continue to benefit from growth in the domestic as well as export markets, while maintaining healthy EBITDA margins led by a moderation in the price erosion in the US generics business, softening of input costs, and high-value product launches in the US generic market.

Aurobindo Pharma is currently trading at Rs. 1012.15, up by 22.75 points or 2.30% from its previous closing of Rs. 989.40 on the BSE.

Alembic Pharmaceuticals is currently trading at Rs. 949.10, up by 14.75 points or 1.58% from its previous closing of Rs. 934.35 on the BSE.

Glenmark Pharmaceuticals is currently trading at Rs. 928.65, up by 9.20 points or 1.00% from its previous closing of Rs. 919.45 on the BSE.

According to report named ‘FY25 Pharmaceuticals Outlook: Moving Up the Value Chain; Sustainable Margins in Sight’, the Indian pharmaceuticals market (IPM) is likely to grow 8%-9% year on year (yoy) in FY25 (FY24: 6%-7% yoy; FY23: 9.3% yoy). It further expects its US-focused pharma issuers to remain stable or report mid-to single-digit revenue growth in FY25 (FY23: 7.2% yoy; 9MFY24: 18.5% yoy) on account of lack of revenue from one-off products. Hence, the overall proportion of sales from the US is likely to remain stable.

The report further noted that the active pharmaceuticals ingredients (API) business of Ind-Ra selected companies is expected to report high single-digit growth in FY25 due to a demand uptick. The overall revenue growth for them is also expected at around 9% yoy while maintaining healthy EBITDA margin performance (around 22%) in FY25. It also said that there has recently been a wave of M&A activity in the domestic formulations space, which is likely to continue.

Alembic Pharma Share Price

764.85 1.30 (0.17%)

22-Apr-2026 12:19 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1660.00
Dr. Reddys Lab	1220.00
Cipla	1234.40
Zydus Lifesciences	931.00
Lupin	2305.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Select pharma stocks gain amid neutral outlook for sector

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.